Literature DB >> 8806678

Bcl-2 and CrmA have different effects on transformation, apoptosis and the stability of I kappa B-alpha in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins.

D W White1, T D Gilmore.   

Abstract

The retroviral oncoprotein v-Rel is a member of the Rel/ NF-kappa B family of transcription factors. We have previously characterized two v-Rel mutants (v-G37E and v-R273H) that are temperature-sensitive (ts) for transformation and immortalization of chicken spleen cells in vitro. We have now constructed vectors for the co-expression of wild-type or ts mutant v-Rel proteins and the anti-apoptosis proteins Bcl-2 or CrmA. The formation of v-Rel-transformed colonies is enhanced in the presence of overexpressed Bcl-2. Moreover, co-expression of Bcl-2 suppresses apoptosis that is induced when ts v-Rel-transformed cells are shifted to the non-permissive temperature. However, co-expression of Bcl-2 in these cells does not affect ts functions of v-Rel, such as DNA binding and stabilization of I kappa B-alpha. In contrast, co-expression of CrmA does not suppress apoptosis, but does block an amino-terminal proteolysis of I kappa B-alpha that occurs in ts v-G37E-transformed cells shifted to the nonpermissive temperature, indicating that an ICE-like protease activity is not involved in apoptosis in these cells but is involved in proteolysis of I kappa B-alpha. In addition, CrmA can block cycloheximide-induced amino-terminal processing of I kappa B-alpha in spleen cells transformed by wild-type v-Rel. In summary, these results suggest that v-Rel immortalizes chicken spleen cells through a pathway that involves the Bcl-2 family of proteins, and suggest that one pathway of proteolysis of I kappa B-alpha involves an ICE-like protease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806678

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Mutations in the v-Rel transactivation domain indicate altered phosphorylation and identify a subset of NF-kappaB-regulated cell death inhibitors important for v-Rel transforming activity.

Authors:  Béatrice Rayet; Yongjun Fan; Céline Gélinas
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

2.  IkappaB is a substrate for a selective pathway of lysosomal proteolysis.

Authors:  A M Cuervo; W Hu; B Lim; J F Dice
Journal:  Mol Biol Cell       Date:  1998-08       Impact factor: 4.138

3.  Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control.

Authors:  Z L Chu; T A McKinsey; L Liu; J J Gentry; M H Malim; D W Ballard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

4.  ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein.

Authors:  M You; P T Ku; R Hrdlicková; H R Bose
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

5.  Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-kappaB.

Authors:  A Z Badrichani; D M Stroka; G Bilbao; D T Curiel; F H Bach; C Ferran
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

6.  Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.

Authors:  Kyoung-Hee Lee; Jiyeong Jeong; Chul-Gyu Yoo
Journal:  J Biol Chem       Date:  2013-10-01       Impact factor: 5.157

7.  Repression of B-cell linker (BLNK) and B-cell adaptor for phosphoinositide 3-kinase (BCAP) is important for lymphocyte transformation by rel proteins.

Authors:  Nupur Gupta; Jeffrey Delrow; Amar Drawid; Anirvan M Sengupta; Gaofeng Fan; Céline Gélinas
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

8.  Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65.

Authors:  D Ferrari; S Wesselborg; M K Bauer; K Schulze-Osthoff
Journal:  J Cell Biol       Date:  1997-12-29       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.